Recombinant Virus Chikungunya Virus E2 Fc Protein

SDS-Page: Chikungunya Virus E2 Recombinant Protein Antigen [NBP3-14819] - Reducing SDS-PAGE gel showing purified Chikungunya E2 envelope protein (Human Fc tag) running with an expected MW of approximately 70-75kDa.

ELISA: Chikungunya Virus E2 Recombinant Protein Antigen [NBP3-14819] - ELISA assay of purified Chikungunya virus E2 envelope protein (Human Fc tag), showing binding of Chikungunya IgM +ve patient sera.

Product Discontinued

Recombinant Virus Chikungunya Virus E2 Fc Protein Summary

• Description: Recombinant gene product from Chikungunya virus (NCBI accession #: Q5XXP3.1, aa 326-693). A glycine-serine linker and Fc-tag was fused to the C-terminus of this recombinant protein.
  
  Tag: Human IgG1 Fc-tag
• Preparation Method: Chikungunya Virus E2 Envelope protein is produced in human cell lines using state-of-the-art expression techniques. This protein is prepared with a human IgG1 Fc-tag, and is purified by Protein A affinity chromatography. We also offer the protein with a mouse IgG2a Fc-tag for those customers where a human Fc-tag may interfere with their assays.
• Source: HEK293
• Protein/Peptide Type: Recombinant Protein
• Purity: >95%

Applications/Dilutions

• Dilutions:
  • ELISA
  • SDS-Page
• Application Notes: Ideal for use in detection of Chikungunya virus via IgG/IgM ELISA or rapid test device.
• Theoretical MW: 69 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.

Reactivity Notes

Chikungunya Virus (Senegal 37997 Strain)

Packaging, Storage & Formulations

• Storage: Store at 4C short term. Aliquot and store at -80C long term. Avoid freeze-thaw cycles.
• Buffer: 20mM HEPES, pH7.0, 300mM NaCl, 0.25% Triton X-100
• Preservative: No Preservative
• Concentration: 0.44 mg/ml
• Purity: >95%

Alternate Names for Recombinant Virus Chikungunya Virus E2 Fc Protein

• Chikungunya
• E2 envelope glycoprotein
• P130
• Spike glycoprotein E2

Background

Chikungunya virus (CHIKV) belongs to the family of alphaviruses and is transmitted by Aedes mosquitoes resulting in infection characterized by symptoms including arthritis-like joint pain and inflammation, fever, rash, and headache (1-3). The CHIKV genome consists of an 11.8 kilobase (kb) positive-sense, single-stranded RNA virus that has two open reading frames (ORFs) (1-3). The first ORF at the 5' end encodes a 2472 amino acid (aa) nonstructural polyprotein and the ORF at the 3' end encodes a 1244 aa structural polyprotein (1-3). The polyproteins generate four nonstructural proteins (nsP1-4) and five structural proteins: capsid (C), envelope E1, E2, E3, and 6K (1-3). The nonstructural proteins comprise CHIKV's RNA replicase (1,2). Structurally, CHIKV has a diameter of ~65 nm and the virion is formed by an icosahedral nucleocapsid shell encapsulating genomic RNA and surrounded by a lipid bilayer envelope (2,3).

Although analysis suggests CHIKV originated in Africa over 500 years ago, first infections weren't reported until the 1950s (1-3). CHIKV has evolved three distinct genotypes, or strains, based on location, termed West African (WA), East/Central/Southern African (ECSA), and Asian (2-3). The WA strain has been most closely associated with enzootic transmission whereas the ECSA strain contributes more to urban epidemics (2). Nonhuman primates are the primary reservoir for the viral host with transmission occurring via mosquitos biting and infecting humans (1-3). Upon acute infection, the virus replicates in cells including fibroblasts and macrophages resulting in innate immune response in infected tissues characterized by infiltrating cells like macrophages, monocytes, natural killer (NK) cells, and lymphocytes (2,3). Infection results in increased production of proinflammatory cytokines such as interferon alpha (IFN-alpha) and interleukin 6 (IL-6), chemokines, and growth factors (2,3). Physical manifestations of infection are high fever, polyarthralgia, headache, arthritis, and rash (1-3). CHIKV symptoms can be confused with other infections like those from dengue fever and Zika virus (1-3). There are no specific antivirals or vaccines for CHIKV, but rather symptoms are treated with antipyretics and non-steroidal anti-inflammatory drugs (NSAIDs) (2,3). While in vitro culture models and in vivo rodent and non-human primate models have been used to study CHIKV pathogenesis and advance our knowledge of the disease, the specific cellular mechanisms are not fully understood (3).

References

1. Vu DM, Jungkind D, Angelle Desiree LaBeaud. Chikungunya Virus. Clin Lab Med. 2017;37(2):371-382. https://doi.org/10.1016/j.cll.2017.01.008

2. Silva LA, Dermody TS. Chikungunya virus: epidemiology, replication, disease mechanisms, and prospective intervention strategies. J Clin Invest. 2017;127(3):737-749. https://doi.org/10.1172/JCI84417

3. Ganesan VK, Duan B, Reid SP. Chikungunya Virus: Pathophysiology, Mechanism, and Modeling. Viruses. 2017;9(12):368. Published 2017 Dec 1. https://doi.org/10.3390/v9120368

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Peptides and proteins are guaranteed for 3 months from date of receipt.